Funding for this research was provided by:
National Cancer Institute (F30 CA180607)
National Institutes of Health (R21 CA223394, R01 CA218802, P30 CA006927)
Received: 21 March 2019
Accepted: 30 May 2019
First Online: 24 June 2019
Ethics approval and consent to participate
: All animal care and experimental procedures were prospectively approved by the Fox Chase Cancer Center Institutional Animal Care and use Committee (IACUC).
: Not applicable.
: Y.B. has served on advisory boards of AbbVie, Astra Zeneca and Caris, and declares no COI. GWL is a founder and a major shareholder in TDL Innovations, LLC. TDL Innovations, LLC is developing therapeutic approaches to treat MPE. E.G. and Y.B. are on the <i>BMC Cancer</i> editorial board. The other authors have no competing interests to disclose.